trovafloxacin has been researched along with alatrofloxacin in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cutler, NR; Dogolo, LC; Jhee, SS; Lucas, G; Sramek, JJ; Teng, R; Vincent, J; Wardle, T | 1 |
| Baris, BA; Friedman, HL; Polzer, RJ; Teng, R; Venitz, J; Vincent, J; Willavize, SA | 1 |
| Dogolo, LC; Friedman, HL; Teng, R; Vincent, J; Willavize, SA | 1 |
| Baris, BA; Dogolo, L; Teng, R; Vincent, J; Willavize, SA | 1 |
| Dogolo, LC; Melnik, G; Schwesinger, WH; Teng, R; Vincent, J | 1 |
| Hopkins, S; Williams, DJ | 1 |
| Ersbøll, J; Renneberg, J; Stenver, DI | 1 |
| Geffken, A; Lacy, MK; Nicolau, DP; Nightingale, CH; Quintiliani, R; Teng, R; Vincent, J | 1 |
| Bradley, JS; Capparelli, EV; Kearns, GL; Reed, MD; Vincent, J | 1 |
| Choudhri, S; Church, D; Grossman, C; Haverstock, D; Herman-Gnjidic, Z; Lode, H; McGivern, J | 1 |
| Hall, IH; Ives, TJ; Schwab, UE; Ward, ES | 1 |
1 review(s) available for trovafloxacin and alatrofloxacin
| Article | Year |
|---|---|
Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Administration Schedule; Drug Interactions; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Naphthyridines; Prodrugs; Surgical Wound Infection | 1998 |
6 trial(s) available for trovafloxacin and alatrofloxacin
| Article | Year |
|---|---|
Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Chromatography, High Pressure Liquid; Double-Blind Method; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Male; Naphthyridines; Prodrugs | 1997 |
Oral bioavailability of trovafloxacin with and without food in healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Biological Availability; Fasting; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Naphthyridines; Prodrugs | 1997 |
Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Drug Administration Schedule; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Naphthyridines; Prodrugs | 1998 |
Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Anti-Infective Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Fluoroquinolones; Half-Life; Humans; Injections, Intravenous; Naphthyridines; Prodrugs; Sample Size | 1999 |
Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
Topics: Adolescent; Anti-Infective Agents; Bacterial Infections; Child; Child, Preschool; Drug Interactions; Fluoroquinolones; Humans; Infant; Injections, Intravenous; Metabolic Clearance Rate; Naphthyridines; Prodrugs | 2000 |
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Pneumonia, Bacterial; Quinolines; Retrospective Studies; Treatment Outcome | 2003 |
5 other study(ies) available for trovafloxacin and alatrofloxacin
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.
Topics: Adolescent; Adult; Anti-Infective Agents; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Naphthyridines; Prodrugs | 1997 |
Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery.
Topics: Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Ascitic Fluid; Colon; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Naphthyridines; Prodrugs; Rectum | 1998 |
[Trovan (trovafloxacin/alatrofloxacin) recalled: why? How?].
Topics: Anti-Infective Agents; Drug and Narcotic Control; European Union; Fluoroquinolones; Humans; Naphthyridines | 1999 |
Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents; Cell Line; Cytokines; Fluoroquinolones; Humans; Monocytes; Naphthyridines; Phagocytosis; Prodrugs; Staphylococcus aureus; Superoxide Dismutase; Time Factors | 2003 |